The BMJ Interview - Andrew Pollard on the Oxford/Astra Zeneca vaccine

episode

Medicine and Science from The BMJ not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

TNB Tech Minute: Nvidia Launches Largest-Ever U.S. Stock Buyback Program 3 min · 28 Sep 2026 · WSJ Tech News Briefing

Erdgas aus Deutschland – Umstrittene Bohrprojekte und die Suche nach Alternativen 28 min · 28 Sep 2026 · Das Wissen | SWR

Phone Tap: All Disabled Parking 10 min · 28 Sep 2026 · Brooke and Jeffrey

Do you guys know what a Chippewa is? | Local Hour 35 min · 28 Sep 2026 · The Dan Le Batard Show

Loser Line (9/28/26) 12 min · 28 Sep 2026 · Brooke and Jeffrey

"We went to support the players" 20 min · 28 Sep 2026 · Liveline

Report any issue

Source

Recorded14 Jan 2021

Publisherfeed.podbean.com ↗

Handlerec:13498074

Show notes

Andrew Pollard is Director of the Oxford Vaccines Group - who, along with Astra Zeneca, have developed an modified adenovirus vaccine for SARS-CoV-2. In this interview we talk to him about the development of that vaccine - what he thinks about the UK government's plan to increase the interval between doses; if he worries about a mutating virus and vaccine escape; and how the university came to make a deal with a commercial company to provide cost-price vaccinations for the world. www.bmj.com/coronavirus

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in